MedTrace Logo

Assessment of the Adjuvant Role of Dietary Supplementation of Antibiotic-tolerant Probiotics in Standard Therapy for the Eradication of Helicobacter Pylori Infection.

NCT06499649 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 270

Last updated 2025-07-08

No results posted yet for this study

Summary

Randomized, double-blind, placebo-controlled clinical study to assess the adjuvant role of dietary supplementation of antibiotic-tolerant probiotics, derived from Lactobacillus acidophilus and Bifidobacterium animalis, in standard therapy for the eradication of Helicobacter pylori infection.

Conditions

  • Helicobacter Pylori Infection

Interventions

DIETARY_SUPPLEMENT

IBSA Probiotics

Dietary supplement base on probiotic strains.

DIETARY_SUPPLEMENT

Placebo

The placebo does not contain functional components, and the appearance is indistinguishable from the comparison product.

Sponsors & Collaborators

  • IBSA Farmaceutici Italia Srl

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-03
Primary Completion
2025-04-30
Completion
2025-05-05

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06499649 on ClinicalTrials.gov